IS-741 (Ishihara Sangyo)
- Curr Opin Investig Drugs. 2001 Apr;2(4):510-2.
- 1. Surgical and Gastroenterological Department, University of Verona, Hospital GB Rossi, Verona, Italy. [email protected]
IS-741 is a Phospholipase A2 (PLA2) inhibitor under development by Ishihara Sangyo Kaisha and Sumitomo as a potential treatment for pancreatitis 1187575]. Sumitomo is developing the drug in phase II trials for acute pancreatitis 13990261. In an animal model, IS-741 has been shown to prevent pancreatitis-associated lung injury following endotoxemia [337503].
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Inflammation/Immunology
-
Research Areas: Inflammation/Immunology
-
Research Areas: Inflammation/Immunology
-
Research Areas: Inflammation/Immunology